Lumiracoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V91T9204HU, chemically known as benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl- but generally known as lumiracoxib, which bears US NIH Compound Identifier 151166. European Medicines Agency schedules Lumiracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21406. The term LUMIRACOXIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 2, 2003, List 49). World Health Organization schedules lumiracoxib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule lumiracoxib under HS 29224995 and SITC 51465. As of Q4 2014, LUMIRACOXIB remains the US FDA Preferred Term for this commodity. Lumiracoxib bears US NLM identifiers UMLS ID C1176415 and NCI Concept Code C66041. SMILES: CLC1C(NC2C(CC(CC2)C)CC(=O)O)C(F)CCC1.